Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373591 · ClinicalTrials.gov registry record · Phase 2
Liposomal Bupivacaine in Bariatric Surgery
A Phase 2 study of Bariatric Surgery Analgesia, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
- 1
- Study location
NCT03373591: Completed Phase 2 study of Bariatric Surgery Analgesia, sponsored by Montefiore Medical Center.
NCT03373591 is a Phase 2 study of Bariatric Surgery Analgesia that has completed, run by Montefiore Medical Center. The registered enrollment target is 219 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373591, a Phase 2 study of Bariatric Surgery Analgesia, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this study, the investigators will assess whether use of long acting local anesthetic can reduce the need for opiates in the bariatric population.
Primary Outcome
Fentanyl PCA (patient controlled analgesia) total microgram usage.
Conditions Studied
Interventions
- DRUG Liposomal Bupivacaine TAP block
- DRUG Bupivacaine TAP block
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
What the finished NCT03373591 record still lists
NCT03373591 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Bariatric Surgery Analgesia appearing as the primary indexed condition, and to 2 interventions - of which Liposomal Bupivacaine TAP block is the first listed.
NCT03373591 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03373591 about?
NCT03373591 is a clinical study titled "Liposomal Bupivacaine in Bariatric Surgery". The aim of this study is to perform a randomized controlled trial for patients undergoing bariatric surgery, comparing the need for opiates with and without administration of a transversus abdominis plane (TAP) block using the long acting local anesthetic, liposomal bupivacaine (Exparel®). From this...
What is the current status of trial NCT03373591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2018-01-30. Estimated completion is 2018-12-31.
What conditions does trial NCT03373591 study?
This clinical trial studies the following conditions: Bariatric Surgery Analgesia.
What interventions are being tested in trial NCT03373591?
The interventions under investigation include: Liposomal Bupivacaine TAP block (DRUG), Bupivacaine TAP block (DRUG).
Who is sponsoring clinical trial NCT03373591?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373591 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03373591's enrollment target sits among peer trials
219 283rd of 2000 higher than 1,717 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT05907980 · 219 participants · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI